Becton, Dickinson and Company (NYSE:BDX) Shares Sold by ASB Consultores LLC

ASB Consultores LLC decreased its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 8.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,111 shares of the medical instruments supplier’s stock after selling 105 shares during the period. ASB Consultores LLC’s holdings in Becton, Dickinson and Company were worth $268,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the company. Livelsberger Financial Advisory bought a new stake in shares of Becton, Dickinson and Company during the 3rd quarter valued at about $26,000. Sound Income Strategies LLC boosted its holdings in shares of Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 44 shares during the period. Opal Wealth Advisors LLC purchased a new position in shares of Becton, Dickinson and Company in the second quarter worth approximately $45,000. Abound Wealth Management raised its holdings in shares of Becton, Dickinson and Company by 96.0% during the second quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock valued at $46,000 after acquiring an additional 96 shares during the period. Finally, Chilton Capital Management LLC lifted its position in shares of Becton, Dickinson and Company by 1,233.3% in the 2nd quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock valued at $47,000 after acquiring an additional 185 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

BDX has been the topic of several recent analyst reports. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Evercore ISI boosted their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Stifel Nicolaus upped their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Finally, Raymond James cut their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $282.63.

Becton, Dickinson and Company Stock Performance

Shares of NYSE:BDX opened at $237.30 on Wednesday. The stock has a market capitalization of $68.59 billion, a P/E ratio of 48.83, a P/E/G ratio of 1.76 and a beta of 0.43. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $259.92. The business has a 50-day moving average price of $237.51 and a two-hundred day moving average price of $235.12.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.